Good Morning – Quick Bold Stock Update on Our Newest Bold Stock

Dear Bold Members:

Below is my alert on QASP from last night. I seriously want you to see the news that came out after the close YESTERDAY!.

SEE IT HERE

My take:

The company is getting SIX total acquisitions funded with these funds. With the FIRST FOUR they reported in August they anticipated $33 million in EBITDA.

QUOTING AN AUGUST RELEASE:

These first four acquisitions of these well established aviation and aerospace related businesses will add an estimated $150 million to Quasar’s revenue and $33 million in EBITDA for the Company’s fiscal year 2010. The first group of acquisitions are only the beginnings of the Quasar Aerospace conglomerate as we are actively pursuing other ventures within the aerospace industry. (READ IT HERE)

This stock has 300% higher in recent months above the current level. The key thing that has depressed this stock for the past three months is the question: “Are they REALLY going to pull this funding off?”

The answer now appears to be YES. We even have details.

The last two releases:

Wed, Nov 18, 2009
• Quasar Aerospace Industries, Inc. Details the Terms of Its $350 Million Funding
Marketwire (Wed 3:37pm)

Fri, Nov 13, 2009
• Quasar Aerospace Industries, Inc. CEO Dean Bradley Announces $350 Million in Funding Is Secured
Marketwire (Fri, Nov 13)

Do you own due diligence. I like QASP, and I see this as one that should now move up since we have more details. Of course the biggest move will come when they get this funding in-house and available to get this plan moving!

Good luck,

Mr. Bold

Below is Last Night’s Announcement of our Bold Stock:

It’s Official… Our Bold Stock for Thursday, November 19, 2009 is Quasar Aerospace Industries, Inc. (Symbol: QASP)

Dear Bold Members:

Bold Stocks was boldly created to bring to you what I consider rather obvious moves in the market – before they happen. Unlike others that seek to CAUSE a movement by bringing an alert to their membership, we seek to bring great stocks at the right moment to our members.

I am announcing a New Bold Stock. As with MZEI, I think it is too important to bring you the alert RIGHT NOW rather than string it out to the open as we do occasionally with funny teases. Those teases do serve the purpose of highlighting the positives and showing you what we like before the market opens, letting the full story come crystal clear at market opening.

Timing is too important here. I ask you to immediately take a look at Quasar Aerospace Industries, Inc. (QASP.PK).

I have been a consultant to the company for about three months. I have helped the company author some of their releases. The big news here is that the company has a $350 million USD funding that is just about to happen. They put out a release just minutes before the market closed on Wednesday. Notice the stock spiked 15.2% in just moments after the release and held that spike to the close. The release hit just 23 minutes before market close.

Here is what I see:

The release on Wednesday DETAILS SPECIFICS including quotes from Mark Lundquist, a Philadelphia based attorney and Senior Vice President for Strategic Planning for Quasar Aerospace Industries, and Dean Bradley, CEO of Quasar Aerospace Industries.

Two paragraphs of the release give explicit details of the funding. QUOTING:

“The funds from the transaction will be transferred to Quasar’s account as lump sum, upon the execution of the final documents. The funding transaction is structured as a loan, the proceeds of which originate as part of a $1 billion bond issued by Inver Finance Ltd., an Irish corporation.

“The bonds, which are secured by $1.4 billion of life settlement policies on individuals over 72 years of age, bear interest at 6.5% with a ten-year term. Under the terms negotiated, interest does not begin accruing until the end of the third year. Additionally, no principal payments become due until the end of the tenth year. Upon maturity of the loan Quasar has three options for repayment: (1) an issuance of the Company’s common stock equal to approximately 9% of the common stock outstanding as payment in full of the principal, (2) extend the loan for two successive five years terms, or (3) pay off the principal and any accrued and unpaid interest.”

Recent Facts:

1. The CEO has been buying shares in the open market. READ THIS

2. The Company itself has been buying shares in the open market. READ THIS

3. The Company is buying planes and training equipment. READ THIS

4. The Company is working on being fully transparent. They gave this update recently – READ THIS

QASP represents a real opportunity as I see it:

You have to balance the good news out with the inherit risk of Pink Sheet stocks.

Get ready for the full market reading what this news means. The news – in my opinion – shows how solid this financing is.

Boldly do your due diligence and consider QASP on Thursday. I think a modest position held for several months would likely be the right move. You have to make the call for yourself, of course.
For more details, see our sister site’s PROFILE of QASP.
Happy Trading!

Mr. Bold

.

.

Most Recent Bold Stock – Prior to QASP:

Our Latest Bold Stock We are Not Going to Create the Suspense of Asking you to Wait a Few Days… Today’s BOLD STOCK is…

OTCBB: MZEI

READ THAT ALERT HERE

Bold Stocks (”Bold”) provides its members with the latest news, press releases, and research reports for all the companies highlighted on our web site, www.BoldStocks.com. Bold utilizes information believed to be reliable herein prepared all material. The information contained herein is not guaranteed by Bold to be accurate, and should not be considered to be all-inclusive. The owner, publisher, editor and their associates are not responsible for errors and omissions. They may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. Any opinions expressed are subject to change without notice. Bold encourages readers and investors to supplement the information in these reports with independent research and other professional advice. All information on featured companies is provided by the companies profiled, or is available from public sources and Bold makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled companies or the information contained herein. The companies that are discussed in this opinion have not approved the statements made in this opinion. This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Bold is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter. Please consult a broker before purchasing or selling any securities viewed onhttp://www.boldstocks.com or mentioned herein. This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected”, “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a companies= annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and Bold undertakes no obligation to update such statements. Pentony Enterprises LLC is occassionally compensated for coverage. When this is the case, we indicate clearly with a disclosure of all compensation received in the past and present, plus we also disclose any anticipated compensation in the future. Compensation is typically in cash. Sometimes a third party shareholder pays us in free trading shares. Sometimes a company pays us in restricted shares. Pentony Enterprises is not a registered investment adviser or a broker/dealer. Pentony Enterprises LLC makes no recommendation that the purchase of securities of companies profiled in this web site is suitable or advisable for any person, or that an investment in such securities will be profitable. In general, given the nature of the companies profiled and the lack of an active trading market for their securities, investing in such securities is highly speculative and carries a high degree of risk. QASP Disclosure: We were compensated $14000 by the company for coverage starting in August and ending on November 25, 2009. We have chosen to put QASP on Bold Stocks although it was not required or requested by the client. We did so based on news and momentum. We anticipate our contract may be renewed at some point in the future for our other coverage. We will update this disclosure if that happens. MZEI Disclosure: Pentony Enterprises LLC was compensated seventy-two hundred dollars and 450,000 144 restricted common shars by the company for profile coverage for the period ending September 15, 2009. Pentony Enterprises is not a registered investment adviser or a broker/dealer. Pentony Enterprises LLC makes no recommendation that the purchase of securities of companies profiled in this web site is suitable or advisable for any person, or that an investment in such securities will be profitable. In general, given the nature of the companies profiled and the lack of an active trading market for their securities, investing in such securities is highly speculative and carries a high degree of risk.

It’s Official… Our Bold Stock for Thursday, November 19, 2009 is Quasar Aerospace Industries, Inc. (Symbol: QASP)

Dear Bold Members:

Bold Stocks was boldly created to bring to you what I consider rather obvious moves in the market – before they happen. Unlike others that seek to CAUSE a movement by bringing an alert to their membership, we seek to bring great stocks at the right moment to our members.

I am announcing a New Bold Stock. As with MZEI, I think it is too important to bring you the alert RIGHT NOW rather than string it out to the open as we do occasionally with funny teases. Those teases do serve the purpose of highlighting the positives and showing you what we like before the market opens, letting the full story come crystal clear at market opening.

Timing is too important here. I ask you to immediately take a look at Quasar Aerospace Industries, Inc. (QASP.PK).

I have been a consultant to the company for about three months. I have helped the company author some of their releases. The big news here is that the company has a $350 million USD funding that is just about to happen. They put out a release just minutes before the market closed on Wednesday. Notice the stock spiked 15.2% in just moments after the release and held that spike to the close. The release hit just 23 minutes before market close.

Here is what I see:

The release on Wednesday DETAILS SPECIFICS including quotes from Mark Lundquist, a Philadelphia based attorney and Senior Vice President for Strategic Planning for Quasar Aerospace Industries, and Dean Bradley, CEO of Quasar Aerospace Industries.

Two paragraphs of the release give explicit details of the funding. QUOTING:

“The funds from the transaction will be transferred to Quasar’s account as lump sum, upon the execution of the final documents. The funding transaction is structured as a loan, the proceeds of which originate as part of a $1 billion bond issued by Inver Finance Ltd., an Irish corporation.

“The bonds, which are secured by $1.4 billion of life settlement policies on individuals over 72 years of age, bear interest at 6.5% with a ten-year term. Under the terms negotiated, interest does not begin accruing until the end of the third year. Additionally, no principal payments become due until the end of the tenth year. Upon maturity of the loan Quasar has three options for repayment: (1) an issuance of the Company’s common stock equal to approximately 9% of the common stock outstanding as payment in full of the principal, (2) extend the loan for two successive five years terms, or (3) pay off the principal and any accrued and unpaid interest.”

Recent Facts:

1. The CEO has been buying shares in the open market. READ THIS

2. The Company itself has been buying shares in the open market. READ THIS

3. The Company is buying planes and training equipment. READ THIS

4. The Company is working on being fully transparent. They gave this update recently – READ THIS

QASP represents a real opportunity as I see it:

You have to balance the good news out with the inherit risk of Pink Sheet stocks.

Get ready for the full market reading what this news means. The news – in my opinion – shows how solid this financing is.

Boldly do your due diligence and consider QASP on Thursday. I think a modest position held for several months would likely be the right move. You have to make the call for yourself, of course.
For more details, see our sister site’s PROFILE of QASP.
Happy Trading!

Mr. Bold

.

.

Most Recent Bold Stock – Prior to QASP:

Our Latest Bold Stock We are Not Going to Create the Suspense of Asking you to Wait a Few Days… Today’s BOLD STOCK is…

OTCBB: MZEI

READ THAT ALERT HERE

Get BOLD STOCKS on TWITTER:

http://twitter.com/boldstocks

Get The BOLD STOCKS RSS FEED:

http://www.boldstocks.com/feed/

To stop receiving these emails please unsubscribe.
Type your Company Name,Bold Stocks (”Bold”) provides its members with the latest news, press releases, and research reports for all the companies highlighted on our web site, www.BoldStocks.com. Bold utilizes information believed to be reliable herein prepared all material. The information contained herein is not guaranteed by Bold to be accurate, and should not be considered to be all-inclusive. The owner, publisher, editor and their associates are not responsible for errors and omissions. They may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. Any opinions expressed are subject to change without notice. Bold encourages readers and investors to supplement the information in these reports with independent research and other professional advice. All information on featured companies is provided by the companies profiled, or is available from public sources and Bold makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled companies or the information contained herein. The companies that are discussed in this opinion have not approved the statements made in this opinion. This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Bold is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter. Please consult a broker before purchasing or selling any securities viewed onhttp://www.boldstocks.com or mentioned herein. This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected”, “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a companies= annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and Bold undertakes no obligation to update such statements. Pentony Enterprises LLC is occassionally compensated for coverage. When this is the case, we indicate clearly with a disclosure of all compensation received in the past and present, plus we also disclose any anticipated compensation in the future. Compensation is typically in cash. Sometimes a third party shareholder pays us in free trading shares. Sometimes a company pays us in restricted shares. Pentony Enterprises is not a registered investment adviser or a broker/dealer. Pentony Enterprises LLC makes no recommendation that the purchase of securities of companies profiled in this web site is suitable or advisable for any person, or that an investment in such securities will be profitable. In general, given the nature of the companies profiled and the lack of an active trading market for their securities, investing in such securities is highly speculative and carries a high degree of risk. QASP Disclosure: We were compensated $14000 by the company for coverage starting in August and ending on November 25, 2009. We have chosen to put QASP on Bold Stocks although it was not required or requested by the client. We did so based on news and momentum. We anticipate our contract may be renewed at some point in the future for our other coverage. We will update this disclosure if that happens. MZEI Disclosure: Pentony Enterprises LLC was compensated seventy-two hundred dollars and 450,000 144 restricted common shars by the company for profile coverage for the period ending September 15, 2009. Pentony Enterprises is not a registered investment adviser or a broker/dealer. Pentony Enterprises LLC makes no recommendation that the purchase of securities of companies profiled in this web site is suitable or advisable for any person, or that an investment in such securities will be profitable. In general, given the nature of the companies profiled and the lack of an active trading market for their securities, investing in such securities is highly speculative and carries a high degree of risk.

Huge News on Recent Bold Stock Skinvisible, Inc. (OTCBB: SKVI) – THIS IS HUGE!

New Clinical Study Proves Skinvisible’s DermSafe Kills the H1N1 Swine Flu Virus

- – - More Positive Results for Unique Hand Sanitizer

Las Vegas, Nevada – November 12, 2009 – Skinvisible, Inc. (SKVI:OTCBB), a pharmaceutical research and development company announced today that it has successfully completed a  new clinical study proving that its hand sanitizer lotion DermSafe® kills/inactivates the H1N1 virus on humans.  This in-vivo study proves that DermSafe meets the criteria set-out by internationally accepted study guidelines to show efficacy against the H1N1 “swine flu” virus.

The study, performed at the independent testing laboratory Bioscience Laboratories, Inc., required that the subjects’ finger pads be contaminated with the H1N1 virus and then examined according to the American Society for Testing and Materials (ASTM) Standards.  The results of the study proved that DermSafe killed the virus to the same detection level as 70% alcohol.  In some countries, this study allows Skinvisible to submit data for approval to include “Kills H1N1” on the product label. This further confirms the efficacy of DermSafe as previously announced in an in-vitro study conducted at Retroscreen Virology, where DermSafe also achieved a 99.99% kill / inactivation of the H1N1 virus.

Furthermore, DermSafe was also successfully tested in an in-vivo bacterial hand disinfection study using the European Standard Method.  This study method is used in a number of countries in Europe and also in Canada for approval in the healthcare and food services industries.  The results proved the efficacy of DermSafe against bacteria on artificially contaminated hands as compared to the reference product of 60% isopropanol, a typical alcohol used in hand sanitizers.

“We are very pleased with the clinical results DermSafe achieved in these two studies,” said Mr. Terry Howlett, President and CEO of Skinvisible.  “This proves that DermSafe is an effective alternative to alcohol, without the drying and safety issues.  It also represents an important milestone to accelerate our license negotiations in various countries as these studies are required for regulatory approval in some jurisdictions.  We also expect these additional studies will solidify and expedite further approvals globally.”

DermSafe is formulated with Skinvisible’s patented technology Invisicare®, a polymer delivery system that is proven to bind to skin and resist wash-off for up to four hours, thereby providing continuous antimicrobial protection. The active ingredient in DermSafe is chlorhexidine gluconate 4%, which has been safely used in hospital surgery rooms worldwide for over fifty years as a pre-surgical hand scrub.

About Invisicare
Invisicare is Skinvisible’s patented polymer delivery system that offers life-cycle management and unique enhancements for topically delivered products.  It is a combination of hydrophilic and hydrophobic polymers that hold active ingredients on the skin for extended periods of time resisting both wash off and perspiration.  Invisicare can control the release of actives and reduce irritation. It is non-occlusive and allows for normal skin respiration while protecting against environmental irritants.  www.invisicare.com

About Skinvisible Pharmaceuticals, Inc
Skinvisible Pharmaceuticals is a research-and-development company whose primary business objective is to license its proprietary formulations with Invisicare to pharmaceutical and cosmeceutical companies as well as assisting companies in enhancing their existing skin care products. Skinvisible receives a combination of research and development fees, upfront license fees, and ongoing royalties for the life of the Invisicare patent. Skinvisible’s value also lies in its ability to continually generate new IP on dermatology and medical products formulated with Invisicare.  www.skinvisible.com

Forward-Looking Statements: This press release contains ‘forward looking’ statements within the meaning of Section 21A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and are subject to the safe harbors created thereby. Such statements involve certain risks and uncertainties associated with an emerging company. Actual results could differ materially from those projected in the forward looking statements as a result of risk factors discussed in Skinvisible, Inc. reports on file with the U.S. Securities and Exchange Commission (including, but not limited to, a report on Form 10K for the quarter ending June 30, 2009).

OUR ORIGINAL RELEASE ON SKVI LAST WEEK:

Dear Bold Members:

Let me introduce you to today’s Bold Stock.  It is Skinvisible, Inc. (OTC Bulletin Board: SKVI).

Let me tell you why this is one of my favorite ones:

1. First – I mentioned in Hint # 1 – QUOTE – “Could not be more timely.”

That is a true understatement. This company anticipated the need for a hand sanitizer that could fight viruses, including “Swine Flu” / aka / “H1N1″ several years back.  They saw the potential need and thought that their exclusive and patented polymers could bind an active ingredient to the hands for four hours to kill certain viruses and bacteria on the hands for up to FOUR HOURS.

I cannot ask you how many times you have been offered or chose to sanitize your hands with hand sanitizer the last few months with some of that alcohol based clear lotion that you now see everywhere. The answer I am sure is countless times.

I am sure you hope all of the food service people have used it recently.  I am sure you hope that everyone that meets your children and comes in contact with the door handles you use also has used such a hand sanitizer just moments before that contact.

What if you could put a hand sanitizer on your hand that lasts for up to four hours?  One that you can even get wet, casually wash in a restroom and it is still there for up to four hours? Wouldn’t that be great.

DermSafe is the product.

That is the product Skinvisible now has ready to bring to market.  It is called DERMSAFE (TM)

Announcement of patent that also covers the polymer in DERMSAFE (TM):

http://finance.yahoo.com/news/Invisicare-Approved-for-pz-3869139635.html

First License Agreement:

http://finance.yahoo.com/news/Skinvisible-Signs-License-pz-1622230259.html

Remember – President Obama declared a “National Emergency” for H1N1.  The primary purpose was to make it easier to get needed help and preventatives in place. Skinvisiable has once presented DERMSAFE (TM) to the FDA under a request for an emergency approval.  Could this make it easier in the future? That is a judgment call.

President Obama on the National Emergency

2. This is a Company that has Been Around – Constant Management & Same Location

This is a company I know.  Like I said in Hint # 3, the company has been in business more than ten years.  More than nine of those years is in the same physical location.  The researchers on staff have done some amazing work over the years, and some of it you can go to any drug store or grocery store in the nation and see.  Below is STOP PAIN, one of their products:

Here is a link to it:

http://shop.stopain.com/

Other products you may have seen:

http://www.skinvisible.com/products.html

3. Great Relationships with Pharmaceutical Companies You Know and Trust

Let’s not name names here, but this is a company that has some great connections with some of the best pharmaceutical companies in the world. They have sold products and licensed an number of products world-wide.

BOTTOM LINE FOR ME:

• Great product, perfect timing, great management, great research staff.

• The product works.

• I see this as one of those rare stocks that has a great SHORT TERM, INTERMEDIATE TERM and LONG TERM potential.  This is one of several products that is marketed on behalf of the company.  This is the one that could bring huge revenues in.

• Last we heard outstanding shares are about 92 million.

• I see a terrific potential here.

WHAT COULD MAKE SKVI BREAK-OUT:

• This is the really good news. The company is now marketing the product. At some point we can likely anticipate news of further successes in that area.

• Could one company come in and buy DERMSAFE?

• Could someone want the entire company?

• There are a myriad of possibilities.  Let’s see how this one shapes up!

• If the Company goes back to the FDA and the FDA grants an Emergency Approval for DERMSAFE (TM).

FINAL THOUGHTS…

I really like this company.  You will note that I only hold restricted shares in SKVI.  I contacted the company and worked out a consulting arrangement with them months ago.  Like you, they were not aware in advance that this company was chosen as our Bold Stock. I will not be selling shares at anytime in 2009.  I can put that in writing to anyone that wants it! I see tremendous potential here.

Thanks,

Mr. Bold

Get BOLD STOCKS on TWITTER:

http://twitter.com/boldstocks

Get The BOLD STOCKS RSS FEED:

http://www.boldstocks.com/feed/

To stop receiving these emails please unsubscribe.
Type your Company Name,Bold Stocks (”Bold”) provides its members with the latest news, press releases, and research reports for all the companies highlighted on our web site, www.BoldStocks.com. Bold utilizes information believed to be reliable herein prepared all material. The information contained herein is not guaranteed by Bold to be accurate, and should not be considered to be all-inclusive. The owner, publisher, editor and their associates are not responsible for errors and omissions. They may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. Any opinions expressed are subject to change without notice. Bold encourages readers and investors to supplement the information in these reports with independent research and other professional advice. All information on featured companies is provided by the companies profiled, or is available from public sources and Bold makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled companies or the information contained herein. The companies that are discussed in this opinion have not approved the statements made in this opinion. This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Bold is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter. Please consult a broker before purchasing or selling any securities viewed onhttp://www.boldstocks.com or mentioned herein. This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected”, “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a companies= annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and Bold undertakes no obligation to update such statements. Pentony Enterprises LLC is occassionally compensated for coverage. When this is the case, we indicate clearly with a disclosure of all compensation received in the past and present, plus we also disclose any anticipated compensation in the future. Compensation is typically in cash. Sometimes a third party shareholder pays us in free trading shares. Sometimes a company pays us in restricted shares. Pentony Enterprises is not a registered investment adviser or a broker/dealer. Pentony Enterprises LLC makes no recommendation that the purchase of securities of companies profiled in this web site is suitable or advisable for any person, or that an investment in such securities will be profitable. In general, given the nature of the companies profiled and the lack of an active trading market for their securities, investing in such securities is highly speculative and carries a high degree of risk.SKVI Disclosure: Pentony Enterprises LLC is STOCKGURU.COM, SHAREHOLDERVISION.COM BOLDSTOCKS.COM and STREETRESEARCH.COM. 10604 Robincreek Lane; Frisco, Texas 75035. (469) 252-3030. Disclosure: Pentony Enterprises LLC has been compensated 500,000 144 restricted common shares by the company for profile coverage for the period ending January 30, 2010. Pentony Enterprises is not a registered investment adviser or a broker/dealer. Pentony Enterprises LLC makes no recommendation that the purchase of securities of companies profiled in this web site is suitable or advisable for any person, or that an investment in such securities will be profitable. In general, given the nature of the companies profiled and the lack of an active trading market for their securities, investing in such securities is highly speculative and carries a high degree of risk.

Our Latest Bold Stock: MZEI – Up a total of 61.76%

Thanks,

With Wednesday’s close of $0.275, that is up 61.76% over the close prior to our start.

REMEMBER: No matter where you read this alert – we are copied in many places – you heard it FIRST on STOCKGURU.COM and BOLDSTOCKS.COM!

Dear Bold Members:

I am thrilled that MZEI did so well for so many. Do keep in mind, the stock is really about saving lives. We have written extensively about MZEI since June 2 on our StockGuru site. To date we can make one categorical statement: We have never, ever sold a share of MZEI. That is personally or in business accounts.

This company is not a play. This is a real company on its way in a very big way.

John Pentony at our StockGuru Site WROTE THIS ABOUT MZEI last night. Please read it. Like with SKVI, we are dedicated to this company. Just because you are going to see another Bold Stock in a few days do not mistake that for “replacing” either MZEI or SKVI.

YES – WE ARE EXPECING ANOTHER BOLD ALERT COMING SOON – DETAILS BY FRIDAY ON WHEN TO EXPECT IT.

BEFORE THEN – EXPECT UPDATES ON MZEI AND SKVI!

Thanks,

Mr. Bold

REMEMBER: No matter where you read this alert – we are copied in many places – you heard it FIRST on STOCKGURU.COM and BOLDSTOCKS.COM!

Get BOLD STOCKS on TWITTER:

http://twitter.com/boldstocks

Get The BOLD STOCKS RSS FEED:

http://www.boldstocks.com/feed/

REMEMBER: No matter where you read this alert – we are copied in many places – you heard it FIRST on STOCKGURU.COM and BOLDSTOCKS.COM!

To stop receiving these emails please unsubscribe.
Type your Company Name,Bold Stocks (”Bold”) provides its members with the latest news, press releases, and research reports for all the companies highlighted on our web site, www.BoldStocks.com. Bold utilizes information believed to be reliable herein prepared all material. The information contained herein is not guaranteed by Bold to be accurate, and should not be considered to be all-inclusive. The owner, publisher, editor and their associates are not responsible for errors and omissions. They may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. Any opinions expressed are subject to change without notice. Bold encourages readers and investors to supplement the information in these reports with independent research and other professional advice. All information on featured companies is provided by the companies profiled, or is available from public sources and Bold makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled companies or the information contained herein. The companies that are discussed in this opinion have not approved the statements made in this opinion. This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Bold is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter. Please consult a broker before purchasing or selling any securities viewed onhttp://www.boldstocks.com or mentioned herein. This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected”, “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a companies= annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and Bold undertakes no obligation to update such statements. Pentony Enterprises LLC is occassionally compensated for coverage. When this is the case, we indicate clearly with a disclosure of all compensation received in the past and present, plus we also disclose any anticipated compensation in the future. Compensation is typically in cash. Sometimes a third party shareholder pays us in free trading shares. Sometimes a company pays us in restricted shares. Pentony Enterprises is not a registered investment adviser or a broker/dealer. Pentony Enterprises LLC makes no recommendation that the purchase of securities of companies profiled in this web site is suitable or advisable for any person, or that an investment in such securities will be profitable. In general, given the nature of the companies profiled and the lack of an active trading market for their securities, investing in such securities is highly speculative and carries a high degree of risk. MZEI Disclosure: Pentony Enterprises LLC was compensated seventy-two hundred dollars and 450,000 144 restricted common shars by the company for profile coverage for the period ending September 15, 2009. Pentony Enterprises is not a registered investment adviser or a broker/dealer. Pentony Enterprises LLC makes no recommendation that the purchase of securities of companies profiled in this web site is suitable or advisable for any person, or that an investment in such securities will be profitable. In general, given the nature of the companies profiled and the lack of an active trading market for their securities, investing in such securities is highly speculative and carries a high degree of risk.

BOLD STOCK ALERT # 2 – DAY TWO – Now Up 47.06% – Volume 1.5 Million Shares

.

OUR ALERTS ARE COPIED ON HUNDREDS OF SITES – GO TO THE SOURCE:

REMEMBER: No matter where you read this alert – we are copied in many places – you heard it FIRST on STOCKGURU.COM and BOLDSTOCKS.COM!

Incredible Chart for Medizone (OTCBB: MZEI)

Credit goes to where it is due… This is from IHUB – HERE IS THE LINK. Click on Chart for LARGER VERSION:

Here is the big release that is causing the stir:

READ THAT RELEASE HERE

MRSA Breakthrough announced for the AsepticSure™ Hospital Sterilization System

Our Earlier Alert:

OTCBB: MZEI

Why Medizone International?:

Dear Bold Members:

This is a stock I know well and have put a lot of time into the past nearly six months. I am a believer in the company. I am a believer in the people behind the company. And – most importantly – I am a believer in the product that is coming. Over the next few days I will be telling you more. Here is a quick synopses:

What problem does their product solve?

The Silent Epidemic

The chart you see above represents the Nosocomial infections outside intensive care units for U.S. hospitals in 2002.

As the notes that came from the source for this chart point out, Nosocomial infections are a huge problem in hospitals today. Although this data is from 2002, the situation has progressively become more serious. Here are the notes that accompanied the chart:

“From the total number of surgical site infections (SSI) obtained from the National Hospital Discharge Dataset and the National Nosocomial Infections Surveillance (NNIS) system, we subtracted the number of SSI among newborns and adults and children in intensive care units. The remaining SSI were among adults and children outside of intensive care units. From hospital-wide surveillance in NNIS, we had the distribution of infectons by major site and calculated the corresponding number of infections for pneumonias (PNEU), urinary tract infections (UTI), bloodstream infections (BSI), and other sites.”

The Impact of Nosocomial Infections in The United States

In 2002, there were approximately 1.7 million total infections. Of these:

• 33,269 occurred among newborns in high-risk nurseries
• 19,059 among newborns in well-baby nurseries
• 417,946 among adults and children in ICUs
• 1,266,851 among adults and children outside of ICUs.

In that year, the estimated deaths in U.S. hospitals were 98,987. Of these:

• 35,967 were for pneumonia
• 30,665 for bloodstream infections
• 13,088 for urinary tract infections
• 8,205 for surgical site infections, and
• 11,062 for infections of other sites.[1]

Nosocomial Infections are an International Problem

In a World Health Organization Survey of 55 hospitals in 14 countries representing four regions, an average 8.7% of hospital patients had nosocomial infections.

What are some of these Infections?

Here is a short list: C-difficile, E-coli, Pseudomonas aeruginous, MRSA and VRE, the main causative agents of hospital derived nosocomial infections.

How bad are some of these?

C. Difficile

C. Difficile is the most serious cause of antibiotic-associated diarrhea (AAD) and can lead to pseudomembranous colitis, a severe infection of the colon, often resulting from eradication of the normal gut flora by antibiotics. Some estimates place the added cost to the healthcare for C. Difficile alone at $17.6 million daily. The CDC estimates that C. Difficile ases in the US may reach 500,000 annually leading to potentially 30,000 deaths.

MRSA

Methicillin-resistant Staphylococcus aureus (MRSA) is a bacterium responsible for difficult-to-treat infections in humans. MRSA are by definition strains of Staphylococcus aureus that are resistant to a large group of antibiotics called the beta-lactams. CDC reported (JAMA, 2007) that the number of serious infections by MRSA in 2006 was close to 100,000, with approximately 19,000 associated deaths.

What is their product?

A Solution: Ozone is a Prime Candidate for use as a Sterilization Agent in Medical Facilities

Many people do not realize that ozone had a long and successful history of use as a potent anti-bacterial, anti-fingal and anti-viral agent. Ozone was first used as a disinfectant in 1881 by Dr. Kellog. In 1893 Ozone was used in the Netherlands for water purification. Presently, in excess of 3,000 municipalities around the world use Ozone for water purification.

Research conducted in New York City has also demonstrated that Ozone is effective against Legionella Bacteria, as well as pseudomonas populations in those water purification plants. Ohio State University (2001) demonstrated a 4 log difference in sporicidal action of Ozone vs. Vaporized Hydrogen Peroxide (6.1 log reduction for Ozone vs. 1.6 log reduction for VHP). Microsearch Laboratories has demonstrated (2007) that Ozone is 3,200 times more effective than chlorine.

Maturity of the stock price… What is the time horizon?

I think the full potential here will not be realized for about three to six months. That said, when you look at what the company is doing and how well it is doing it, you have to think they will have a great market..

Thanks,

Mr. Bold

Get BOLD STOCKS on TWITTER:

http://twitter.com/boldstocks

Get The BOLD STOCKS RSS FEED:

http://www.boldstocks.com/feed/

To stop receiving these emails please unsubscribe.
Type your Company Name,Bold Stocks (”Bold”) provides its members with the latest news, press releases, and research reports for all the companies highlighted on our web site, www.BoldStocks.com. Bold utilizes information believed to be reliable herein prepared all material. The information contained herein is not guaranteed by Bold to be accurate, and should not be considered to be all-inclusive. The owner, publisher, editor and their associates are not responsible for errors and omissions. They may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. Any opinions expressed are subject to change without notice. Bold encourages readers and investors to supplement the information in these reports with independent research and other professional advice. All information on featured companies is provided by the companies profiled, or is available from public sources and Bold makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled companies or the information contained herein. The companies that are discussed in this opinion have not approved the statements made in this opinion. This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Bold is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter. Please consult a broker before purchasing or selling any securities viewed onhttp://www.boldstocks.com or mentioned herein. This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected”, “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a companies= annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and Bold undertakes no obligation to update such statements. Pentony Enterprises LLC is occassionally compensated for coverage. When this is the case, we indicate clearly with a disclosure of all compensation received in the past and present, plus we also disclose any anticipated compensation in the future. Compensation is typically in cash. Sometimes a third party shareholder pays us in free trading shares. Sometimes a company pays us in restricted shares. Pentony Enterprises is not a registered investment adviser or a broker/dealer. Pentony Enterprises LLC makes no recommendation that the purchase of securities of companies profiled in this web site is suitable or advisable for any person, or that an investment in such securities will be profitable. In general, given the nature of the companies profiled and the lack of an active trading market for their securities, investing in such securities is highly speculative and carries a high degree of risk. MZEI Disclosure: Pentony Enterprises LLC was compensated seventy-two hundred dollars and 450,000 144 restricted common shars by the company for profile coverage for the period ending September 15, 2009. Pentony Enterprises is not a registered investment adviser or a broker/dealer. Pentony Enterprises LLC makes no recommendation that the purchase of securities of companies profiled in this web site is suitable or advisable for any person, or that an investment in such securities will be profitable. In general, given the nature of the companies profiled and the lack of an active trading market for their securities, investing in such securities is highly speculative and carries a high degree of risk.

More on Tuesday’s Bold Stock:

.

BOLD STOCK – DAY TWO – BREAKOUT CONTINUES – UP 35.29%

TODAY’S VOLUME – INCREDIBLE AT 369,650 IN FIRST 30 MINUTES

.

OUR ALERTS ARE COPIED ON HUNDREDS OF SITES – GO TO THE SOURCE:

REMEMBER: No matter where you read this alert – we are copied in many places – you heard it FIRST on STOCKGURU.COM and BOLDSTOCKS.COM!

Incredible Chart for Medizone (OTCBB: MZEI)

Credit goes to where it is due… This is from IHUB – HERE IS THE LINK. Click on Chart for LARGER VERSION:

Here is the big release that is causing the stir:

READ THAT RELEASE HERE

MRSA Breakthrough announced for the AsepticSure™ Hospital Sterilization System

Our Earlier Alert:

OTCBB: MZEI

Why Medizone International?:

Dear Bold Members:

This is a stock I know well and have put a lot of time into the past nearly six months. I am a believer in the company. I am a believer in the people behind the company. And – most importantly – I am a believer in the product that is coming. Over the next few days I will be telling you more. Here is a quick synopses:

What problem does their product solve?

The Silent Epidemic

The chart you see above represents the Nosocomial infections outside intensive care units for U.S. hospitals in 2002.

As the notes that came from the source for this chart point out, Nosocomial infections are a huge problem in hospitals today. Although this data is from 2002, the situation has progressively become more serious. Here are the notes that accompanied the chart:

“From the total number of surgical site infections (SSI) obtained from the National Hospital Discharge Dataset and the National Nosocomial Infections Surveillance (NNIS) system, we subtracted the number of SSI among newborns and adults and children in intensive care units. The remaining SSI were among adults and children outside of intensive care units. From hospital-wide surveillance in NNIS, we had the distribution of infectons by major site and calculated the corresponding number of infections for pneumonias (PNEU), urinary tract infections (UTI), bloodstream infections (BSI), and other sites.”

The Impact of Nosocomial Infections in The United States

In 2002, there were approximately 1.7 million total infections. Of these:

• 33,269 occurred among newborns in high-risk nurseries
• 19,059 among newborns in well-baby nurseries
• 417,946 among adults and children in ICUs
• 1,266,851 among adults and children outside of ICUs.

In that year, the estimated deaths in U.S. hospitals were 98,987. Of these:

• 35,967 were for pneumonia
• 30,665 for bloodstream infections
• 13,088 for urinary tract infections
• 8,205 for surgical site infections, and
• 11,062 for infections of other sites.[1]

Nosocomial Infections are an International Problem

In a World Health Organization Survey of 55 hospitals in 14 countries representing four regions, an average 8.7% of hospital patients had nosocomial infections.

What are some of these Infections?

Here is a short list: C-difficile, E-coli, Pseudomonas aeruginous, MRSA and VRE, the main causative agents of hospital derived nosocomial infections.

How bad are some of these?

C. Difficile

C. Difficile is the most serious cause of antibiotic-associated diarrhea (AAD) and can lead to pseudomembranous colitis, a severe infection of the colon, often resulting from eradication of the normal gut flora by antibiotics. Some estimates place the added cost to the healthcare for C. Difficile alone at $17.6 million daily. The CDC estimates that C. Difficile ases in the US may reach 500,000 annually leading to potentially 30,000 deaths.

MRSA

Methicillin-resistant Staphylococcus aureus (MRSA) is a bacterium responsible for difficult-to-treat infections in humans. MRSA are by definition strains of Staphylococcus aureus that are resistant to a large group of antibiotics called the beta-lactams. CDC reported (JAMA, 2007) that the number of serious infections by MRSA in 2006 was close to 100,000, with approximately 19,000 associated deaths.

What is their product?

A Solution: Ozone is a Prime Candidate for use as a Sterilization Agent in Medical Facilities

Many people do not realize that ozone had a long and successful history of use as a potent anti-bacterial, anti-fingal and anti-viral agent. Ozone was first used as a disinfectant in 1881 by Dr. Kellog. In 1893 Ozone was used in the Netherlands for water purification. Presently, in excess of 3,000 municipalities around the world use Ozone for water purification.

Research conducted in New York City has also demonstrated that Ozone is effective against Legionella Bacteria, as well as pseudomonas populations in those water purification plants. Ohio State University (2001) demonstrated a 4 log difference in sporicidal action of Ozone vs. Vaporized Hydrogen Peroxide (6.1 log reduction for Ozone vs. 1.6 log reduction for VHP). Microsearch Laboratories has demonstrated (2007) that Ozone is 3,200 times more effective than chlorine.

Maturity of the stock price… What is the time horizon?

I think the full potential here will not be realized for about three to six months. That said, when you look at what the company is doing and how well it is doing it, you have to think they will have a great market..

Thanks,

Mr. Bold

Get BOLD STOCKS on TWITTER:

http://twitter.com/boldstocks

Get The BOLD STOCKS RSS FEED:

http://www.boldstocks.com/feed/

To stop receiving these emails please unsubscribe.
Type your Company Name,Bold Stocks (”Bold”) provides its members with the latest news, press releases, and research reports for all the companies highlighted on our web site, www.BoldStocks.com. Bold utilizes information believed to be reliable herein prepared all material. The information contained herein is not guaranteed by Bold to be accurate, and should not be considered to be all-inclusive. The owner, publisher, editor and their associates are not responsible for errors and omissions. They may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. Any opinions expressed are subject to change without notice. Bold encourages readers and investors to supplement the information in these reports with independent research and other professional advice. All information on featured companies is provided by the companies profiled, or is available from public sources and Bold makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled companies or the information contained herein. The companies that are discussed in this opinion have not approved the statements made in this opinion. This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Bold is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter. Please consult a broker before purchasing or selling any securities viewed onhttp://www.boldstocks.com or mentioned herein. This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected”, “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a companies= annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and Bold undertakes no obligation to update such statements. Pentony Enterprises LLC is occassionally compensated for coverage. When this is the case, we indicate clearly with a disclosure of all compensation received in the past and present, plus we also disclose any anticipated compensation in the future. Compensation is typically in cash. Sometimes a third party shareholder pays us in free trading shares. Sometimes a company pays us in restricted shares. Pentony Enterprises is not a registered investment adviser or a broker/dealer. Pentony Enterprises LLC makes no recommendation that the purchase of securities of companies profiled in this web site is suitable or advisable for any person, or that an investment in such securities will be profitable. In general, given the nature of the companies profiled and the lack of an active trading market for their securities, investing in such securities is highly speculative and carries a high degree of risk. MZEI Disclosure: Pentony Enterprises LLC was compensated seventy-two hundred dollars and 450,000 144 restricted common shars by the company for profile coverage for the period ending September 15, 2009. Pentony Enterprises is not a registered investment adviser or a broker/dealer. Pentony Enterprises LLC makes no recommendation that the purchase of securities of companies profiled in this web site is suitable or advisable for any person, or that an investment in such securities will be profitable. In general, given the nature of the companies profiled and the lack of an active trading market for their securities, investing in such securities is highly speculative and carries a high degree of risk.

More on Tuesday’s Bold Stock:

Incredible Chart for Medizone (OTCBB: MZEI)

Credit goes to where it is due… This is from IHUB – HERE IS THE LINK. Click on Chart for LARGER VERSION:

Here is the big release that is causing the stir:

READ THAT RELEASE HERE

MRSA Breakthrough announced for the AsepticSure™ Hospital Sterilization System

Our Earlier Alert:

OTCBB: MZEI

Why Medizone International?:

Dear Bold Members:

This is a stock I know well and have put a lot of time into the past nearly six months. I am a believer in the company. I am a believer in the people behind the company. And – most importantly – I am a believer in the product that is coming. Over the next few days I will be telling you more. Here is a quick synopses:

What problem does their product solve?

The Silent Epidemic

The chart you see above represents the Nosocomial infections outside intensive care units for U.S. hospitals in 2002.

As the notes that came from the source for this chart point out, Nosocomial infections are a huge problem in hospitals today. Although this data is from 2002, the situation has progressively become more serious. Here are the notes that accompanied the chart:

“From the total number of surgical site infections (SSI) obtained from the National Hospital Discharge Dataset and the National Nosocomial Infections Surveillance (NNIS) system, we subtracted the number of SSI among newborns and adults and children in intensive care units. The remaining SSI were among adults and children outside of intensive care units. From hospital-wide surveillance in NNIS, we had the distribution of infectons by major site and calculated the corresponding number of infections for pneumonias (PNEU), urinary tract infections (UTI), bloodstream infections (BSI), and other sites.”

The Impact of Nosocomial Infections in The United States

In 2002, there were approximately 1.7 million total infections. Of these:

• 33,269 occurred among newborns in high-risk nurseries
• 19,059 among newborns in well-baby nurseries
• 417,946 among adults and children in ICUs
• 1,266,851 among adults and children outside of ICUs.

In that year, the estimated deaths in U.S. hospitals were 98,987. Of these:

• 35,967 were for pneumonia
• 30,665 for bloodstream infections
• 13,088 for urinary tract infections
• 8,205 for surgical site infections, and
• 11,062 for infections of other sites.[1]

Nosocomial Infections are an International Problem

In a World Health Organization Survey of 55 hospitals in 14 countries representing four regions, an average 8.7% of hospital patients had nosocomial infections.

What are some of these Infections?

Here is a short list: C-difficile, E-coli, Pseudomonas aeruginous, MRSA and VRE, the main causative agents of hospital derived nosocomial infections.

How bad are some of these?

C. Difficile

C. Difficile is the most serious cause of antibiotic-associated diarrhea (AAD) and can lead to pseudomembranous colitis, a severe infection of the colon, often resulting from eradication of the normal gut flora by antibiotics. Some estimates place the added cost to the healthcare for C. Difficile alone at $17.6 million daily. The CDC estimates that C. Difficile ases in the US may reach 500,000 annually leading to potentially 30,000 deaths.

MRSA

Methicillin-resistant Staphylococcus aureus (MRSA) is a bacterium responsible for difficult-to-treat infections in humans. MRSA are by definition strains of Staphylococcus aureus that are resistant to a large group of antibiotics called the beta-lactams. CDC reported (JAMA, 2007) that the number of serious infections by MRSA in 2006 was close to 100,000, with approximately 19,000 associated deaths.

What is their product?

A Solution: Ozone is a Prime Candidate for use as a Sterilization Agent in Medical Facilities

Many people do not realize that ozone had a long and successful history of use as a potent anti-bacterial, anti-fingal and anti-viral agent. Ozone was first used as a disinfectant in 1881 by Dr. Kellog. In 1893 Ozone was used in the Netherlands for water purification. Presently, in excess of 3,000 municipalities around the world use Ozone for water purification.

Research conducted in New York City has also demonstrated that Ozone is effective against Legionella Bacteria, as well as pseudomonas populations in those water purification plants. Ohio State University (2001) demonstrated a 4 log difference in sporicidal action of Ozone vs. Vaporized Hydrogen Peroxide (6.1 log reduction for Ozone vs. 1.6 log reduction for VHP). Microsearch Laboratories has demonstrated (2007) that Ozone is 3,200 times more effective than chlorine.

Maturity of the stock price… What is the time horizon?

I think the full potential here will not be realized for about three to six months. That said, when you look at what the company is doing and how well it is doing it, you have to think they will have a great market..

Thanks,

Mr. Bold

Get BOLD STOCKS on TWITTER:

http://twitter.com/boldstocks

Get The BOLD STOCKS RSS FEED:

http://www.boldstocks.com/feed/

To stop receiving these emails please unsubscribe.
Type your Company Name,Bold Stocks (”Bold”) provides its members with the latest news, press releases, and research reports for all the companies highlighted on our web site, www.BoldStocks.com. Bold utilizes information believed to be reliable herein prepared all material. The information contained herein is not guaranteed by Bold to be accurate, and should not be considered to be all-inclusive. The owner, publisher, editor and their associates are not responsible for errors and omissions. They may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. Any opinions expressed are subject to change without notice. Bold encourages readers and investors to supplement the information in these reports with independent research and other professional advice. All information on featured companies is provided by the companies profiled, or is available from public sources and Bold makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled companies or the information contained herein. The companies that are discussed in this opinion have not approved the statements made in this opinion. This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Bold is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter. Please consult a broker before purchasing or selling any securities viewed onhttp://www.boldstocks.com or mentioned herein. This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected”, “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a companies= annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and Bold undertakes no obligation to update such statements. Pentony Enterprises LLC is occassionally compensated for coverage. When this is the case, we indicate clearly with a disclosure of all compensation received in the past and present, plus we also disclose any anticipated compensation in the future. Compensation is typically in cash. Sometimes a third party shareholder pays us in free trading shares. Sometimes a company pays us in restricted shares. Pentony Enterprises is not a registered investment adviser or a broker/dealer. Pentony Enterprises LLC makes no recommendation that the purchase of securities of companies profiled in this web site is suitable or advisable for any person, or that an investment in such securities will be profitable. In general, given the nature of the companies profiled and the lack of an active trading market for their securities, investing in such securities is highly speculative and carries a high degree of risk. MZEI Disclosure: Pentony Enterprises LLC was compensated seventy-two hundred dollars and 450,000 144 restricted common shars by the company for profile coverage for the period ending September 15, 2009. Pentony Enterprises is not a registered investment adviser or a broker/dealer. Pentony Enterprises LLC makes no recommendation that the purchase of securities of companies profiled in this web site is suitable or advisable for any person, or that an investment in such securities will be profitable. In general, given the nature of the companies profiled and the lack of an active trading market for their securities, investing in such securities is highly speculative and carries a high degree of risk.

Breaking News on Today’s Bold Stock:

Alert # 2: Today’s BOLD STOCK is now up 21.5% and is Breaking-out on its announcement of a Breakthrough in Fighting MRSA

READ THAT RELEASE HERE

MRSA Breakthrough announced for the AsepticSure™ Hospital Sterilization System

Type your Company Name,Bold Stocks (”Bold”) provides its members with the latest news, press releases, and research reports for all the companies highlighted on our web site, www.BoldStocks.com. Bold utilizes information believed to be reliable herein prepared all material. The information contained herein is not guaranteed by Bold to be accurate, and should not be considered to be all-inclusive. The owner, publisher, editor and their associates are not responsible for errors and omissions. They may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. Any opinions expressed are subject to change without notice. Bold encourages readers and investors to supplement the information in these reports with independent research and other professional advice. All information on featured companies is provided by the companies profiled, or is available from public sources and Bold makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled companies or the information contained herein. The companies that are discussed in this opinion have not approved the statements made in this opinion. This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Bold is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter. Please consult a broker before purchasing or selling any securities viewed onhttp://www.boldstocks.com or mentioned herein. This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected”, “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a companies= annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and Bold undertakes no obligation to update such statements. Pentony Enterprises LLC is occassionally compensated for coverage. When this is the case, we indicate clearly with a disclosure of all compensation received in the past and present, plus we also disclose any anticipated compensation in the future. Compensation is typically in cash. Sometimes a third party shareholder pays us in free trading shares. Sometimes a company pays us in restricted shares. Pentony Enterprises is not a registered investment adviser or a broker/dealer. Pentony Enterprises LLC makes no recommendation that the purchase of securities of companies profiled in this web site is suitable or advisable for any person, or that an investment in such securities will be profitable. In general, given the nature of the companies profiled and the lack of an active trading market for their securities, investing in such securities is highly speculative and carries a high degree of risk. MZEI Disclosure: Pentony Enterprises LLC was compensated seventy-two hundred dollars and 450,000 144 restricted common shars by the company for profile coverage for the period ending September 15, 2009. Pentony Enterprises is not a registered investment adviser or a broker/dealer. Pentony Enterprises LLC makes no recommendation that the purchase of securities of companies profiled in this web site is suitable or advisable for any person, or that an investment in such securities will be profitable. In general, given the nature of the companies profiled and the lack of an active trading market for their securities, investing in such securities is highly speculative and carries a high degree of risk.

Breaking News on Today’s Bold Stock:

Today’s BOLD STOCK is up 17.65% and is Breaking-out on its announcement of a Breakthrough in Fighting MRSA

READ THAT RELEASE HERE

MRSA Breakthrough announced for the AsepticSure™ Hospital Sterilization System

Our Earlier Alert:

OTCBB: MZEI

Why Medizone International?:

Dear Bold Members:

This is a stock I know well and have put a lot of time into the past nearly six months. I am a believer in the company. I am a believer in the people behind the company. And – most importantly – I am a believer in the product that is coming. Over the next few days I will be telling you more. Here is a quick synopses:

What problem does their product solve?

The Silent Epidemic

The chart you see above represents the Nosocomial infections outside intensive care units for U.S. hospitals in 2002.

As the notes that came from the source for this chart point out, Nosocomial infections are a huge problem in hospitals today. Although this data is from 2002, the situation has progressively become more serious. Here are the notes that accompanied the chart:

“From the total number of surgical site infections (SSI) obtained from the National Hospital Discharge Dataset and the National Nosocomial Infections Surveillance (NNIS) system, we subtracted the number of SSI among newborns and adults and children in intensive care units. The remaining SSI were among adults and children outside of intensive care units. From hospital-wide surveillance in NNIS, we had the distribution of infectons by major site and calculated the corresponding number of infections for pneumonias (PNEU), urinary tract infections (UTI), bloodstream infections (BSI), and other sites.”

The Impact of Nosocomial Infections in The United States

In 2002, there were approximately 1.7 million total infections. Of these:

• 33,269 occurred among newborns in high-risk nurseries
• 19,059 among newborns in well-baby nurseries
• 417,946 among adults and children in ICUs
• 1,266,851 among adults and children outside of ICUs.

In that year, the estimated deaths in U.S. hospitals were 98,987. Of these:

• 35,967 were for pneumonia
• 30,665 for bloodstream infections
• 13,088 for urinary tract infections
• 8,205 for surgical site infections, and
• 11,062 for infections of other sites.[1]

Nosocomial Infections are an International Problem

In a World Health Organization Survey of 55 hospitals in 14 countries representing four regions, an average 8.7% of hospital patients had nosocomial infections.

What are some of these Infections?

Here is a short list: C-difficile, E-coli, Pseudomonas aeruginous, MRSA and VRE, the main causative agents of hospital derived nosocomial infections.

How bad are some of these?

C. Difficile

C. Difficile is the most serious cause of antibiotic-associated diarrhea (AAD) and can lead to pseudomembranous colitis, a severe infection of the colon, often resulting from eradication of the normal gut flora by antibiotics. Some estimates place the added cost to the healthcare for C. Difficile alone at $17.6 million daily. The CDC estimates that C. Difficile ases in the US may reach 500,000 annually leading to potentially 30,000 deaths.

MRSA

Methicillin-resistant Staphylococcus aureus (MRSA) is a bacterium responsible for difficult-to-treat infections in humans. MRSA are by definition strains of Staphylococcus aureus that are resistant to a large group of antibiotics called the beta-lactams. CDC reported (JAMA, 2007) that the number of serious infections by MRSA in 2006 was close to 100,000, with approximately 19,000 associated deaths.

What is their product?

A Solution: Ozone is a Prime Candidate for use as a Sterilization Agent in Medical Facilities

Many people do not realize that ozone had a long and successful history of use as a potent anti-bacterial, anti-fingal and anti-viral agent. Ozone was first used as a disinfectant in 1881 by Dr. Kellog. In 1893 Ozone was used in the Netherlands for water purification. Presently, in excess of 3,000 municipalities around the world use Ozone for water purification.

Research conducted in New York City has also demonstrated that Ozone is effective against Legionella Bacteria, as well as pseudomonas populations in those water purification plants. Ohio State University (2001) demonstrated a 4 log difference in sporicidal action of Ozone vs. Vaporized Hydrogen Peroxide (6.1 log reduction for Ozone vs. 1.6 log reduction for VHP). Microsearch Laboratories has demonstrated (2007) that Ozone is 3,200 times more effective than chlorine.

Maturity of the stock price… What is the time horizon?

I think the full potential here will not be realized for about three to six months. That said, when you look at what the company is doing and how well it is doing it, you have to think they will have a great market..

Thanks,

Mr. Bold

Get BOLD STOCKS on TWITTER:

http://twitter.com/boldstocks

Get The BOLD STOCKS RSS FEED:

http://www.boldstocks.com/feed/

To stop receiving these emails please unsubscribe.
Type your Company Name,Bold Stocks (”Bold”) provides its members with the latest news, press releases, and research reports for all the companies highlighted on our web site, www.BoldStocks.com. Bold utilizes information believed to be reliable herein prepared all material. The information contained herein is not guaranteed by Bold to be accurate, and should not be considered to be all-inclusive. The owner, publisher, editor and their associates are not responsible for errors and omissions. They may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. Any opinions expressed are subject to change without notice. Bold encourages readers and investors to supplement the information in these reports with independent research and other professional advice. All information on featured companies is provided by the companies profiled, or is available from public sources and Bold makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled companies or the information contained herein. The companies that are discussed in this opinion have not approved the statements made in this opinion. This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Bold is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter. Please consult a broker before purchasing or selling any securities viewed onhttp://www.boldstocks.com or mentioned herein. This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected”, “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a companies= annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and Bold undertakes no obligation to update such statements. Pentony Enterprises LLC is occassionally compensated for coverage. When this is the case, we indicate clearly with a disclosure of all compensation received in the past and present, plus we also disclose any anticipated compensation in the future. Compensation is typically in cash. Sometimes a third party shareholder pays us in free trading shares. Sometimes a company pays us in restricted shares. Pentony Enterprises is not a registered investment adviser or a broker/dealer. Pentony Enterprises LLC makes no recommendation that the purchase of securities of companies profiled in this web site is suitable or advisable for any person, or that an investment in such securities will be profitable. In general, given the nature of the companies profiled and the lack of an active trading market for their securities, investing in such securities is highly speculative and carries a high degree of risk. MZEI Disclosure: Pentony Enterprises LLC was compensated seventy-two hundred dollars and 450,000 144 restricted common shars by the company for profile coverage for the period ending September 15, 2009. Pentony Enterprises is not a registered investment adviser or a broker/dealer. Pentony Enterprises LLC makes no recommendation that the purchase of securities of companies profiled in this web site is suitable or advisable for any person, or that an investment in such securities will be profitable. In general, given the nature of the companies profiled and the lack of an active trading market for their securities, investing in such securities is highly speculative and carries a high degree of risk.

Breaking News on Today’s Bold Stock:

MZEI Breaking News – A Break-though in Fighting MRSA:

MRSA Breakthrough announced for the AsepticSure™ Hospital Sterilization System

Publisher’s Note: This is huge. See highlighted section.

San Francisco, California, Medizone International, Inc. (MZEI.OB) announces that following several months of research, AsepticSure™ can now achieve a level of bacterial decontamination heretofore unseen in open space settings using conventional means. Dr Michael E. Shannon, Director of Medical Affairs, Medizone International stated, “our research team has pressed hard over the last few months to systematically evaluate various decontamination options involving numerous technological approaches in combination, and to our surprise, we have managed reliably and predictably to break through the 6 log barrier with MRSA. This unexpected development will significantly expand the utility for AsepticSure™, since by definition, any bacterial reduction beyond 6 logs (99.9999%) is considered STERILIZATION. This unique combination of technologies and protocols will now be tested on C difficile, E coli, Pseudomonas aeruginous, and VRE with the expectation that AsepticSure™ will achieve the same degree of incremental improvement over the 4 to 5 log reductions we have already demonstrated with those pathogens in earlier trials.”

Medizone International is preparing a second patent filing to cover these developments while construction and instrumentation of an expanded laboratory setting at the company’s Innovation Park, Queens University laboratory continues in preparation for full room scale-up testing of its equipment to commence in December.

Medizone International, Inc., is a research and development company engaged in developing its’

AsepticSure™ technology to decontaminate and sterilize hospital surgical suites, emergency rooms,

intensive care units, schools and other critical infrastructure. Current trials are now being expanded to include a hospital mock-up to be followed by hospital beta testing. Initial sales are targeted to commence early in 2010.

This Press Release contains certain forward looking statements that involve substantial risks and uncertainties, including, but not limited to, the results of ongoing clinical studies, economic conditions, product and technology development, production efficiencies, product demand, competitive products, competitive environment, successful testing and government regulatory issues. Additional risks are identified in the company’s filings made with the Securities and Exchange Commission.

Investor Relations: 415-868-0300 / web site: www.medizoneint.com

E-mail: operations@medizoneint.com

Our Earlier Alert:

OTCBB: MZEI

Why Medizone International?:

Dear Bold Members:

This is a stock I know well and have put a lot of time into the past nearly six months. I am a believer in the company. I am a believer in the people behind the company. And – most importantly – I am a believer in the product that is coming. Over the next few days I will be telling you more. Here is a quick synopses:

What problem does their product solve?

The Silent Epidemic

The chart you see above represents the Nosocomial infections outside intensive care units for U.S. hospitals in 2002.

As the notes that came from the source for this chart point out, Nosocomial infections are a huge problem in hospitals today. Although this data is from 2002, the situation has progressively become more serious. Here are the notes that accompanied the chart:

“From the total number of surgical site infections (SSI) obtained from the National Hospital Discharge Dataset and the National Nosocomial Infections Surveillance (NNIS) system, we subtracted the number of SSI among newborns and adults and children in intensive care units. The remaining SSI were among adults and children outside of intensive care units. From hospital-wide surveillance in NNIS, we had the distribution of infectons by major site and calculated the corresponding number of infections for pneumonias (PNEU), urinary tract infections (UTI), bloodstream infections (BSI), and other sites.”

The Impact of Nosocomial Infections in The United States

In 2002, there were approximately 1.7 million total infections. Of these:

• 33,269 occurred among newborns in high-risk nurseries
• 19,059 among newborns in well-baby nurseries
• 417,946 among adults and children in ICUs
• 1,266,851 among adults and children outside of ICUs.

In that year, the estimated deaths in U.S. hospitals were 98,987. Of these:

• 35,967 were for pneumonia
• 30,665 for bloodstream infections
• 13,088 for urinary tract infections
• 8,205 for surgical site infections, and
• 11,062 for infections of other sites.[1]

Nosocomial Infections are an International Problem

In a World Health Organization Survey of 55 hospitals in 14 countries representing four regions, an average 8.7% of hospital patients had nosocomial infections.

What are some of these Infections?

Here is a short list: C-difficile, E-coli, Pseudomonas aeruginous, MRSA and VRE, the main causative agents of hospital derived nosocomial infections.

How bad are some of these?

C. Difficile

C. Difficile is the most serious cause of antibiotic-associated diarrhea (AAD) and can lead to pseudomembranous colitis, a severe infection of the colon, often resulting from eradication of the normal gut flora by antibiotics. Some estimates place the added cost to the healthcare for C. Difficile alone at $17.6 million daily. The CDC estimates that C. Difficile ases in the US may reach 500,000 annually leading to potentially 30,000 deaths.

MRSA

Methicillin-resistant Staphylococcus aureus (MRSA) is a bacterium responsible for difficult-to-treat infections in humans. MRSA are by definition strains of Staphylococcus aureus that are resistant to a large group of antibiotics called the beta-lactams. CDC reported (JAMA, 2007) that the number of serious infections by MRSA in 2006 was close to 100,000, with approximately 19,000 associated deaths.

What is their product?

A Solution: Ozone is a Prime Candidate for use as a Sterilization Agent in Medical Facilities

Many people do not realize that ozone had a long and successful history of use as a potent anti-bacterial, anti-fingal and anti-viral agent. Ozone was first used as a disinfectant in 1881 by Dr. Kellog. In 1893 Ozone was used in the Netherlands for water purification. Presently, in excess of 3,000 municipalities around the world use Ozone for water purification.

Research conducted in New York City has also demonstrated that Ozone is effective against Legionella Bacteria, as well as pseudomonas populations in those water purification plants. Ohio State University (2001) demonstrated a 4 log difference in sporicidal action of Ozone vs. Vaporized Hydrogen Peroxide (6.1 log reduction for Ozone vs. 1.6 log reduction for VHP). Microsearch Laboratories has demonstrated (2007) that Ozone is 3,200 times more effective than chlorine.

Maturity of the stock price… What is the time horizon?

I think the full potential here will not be realized for about three to six months. That said, when you look at what the company is doing and how well it is doing it, you have to think they will have a great market..

Thanks,

Mr. Bold

Get BOLD STOCKS on TWITTER:

http://twitter.com/boldstocks

Get The BOLD STOCKS RSS FEED:

http://www.boldstocks.com/feed/

To stop receiving these emails please unsubscribe.
Type your Company Name,Bold Stocks (”Bold”) provides its members with the latest news, press releases, and research reports for all the companies highlighted on our web site, www.BoldStocks.com. Bold utilizes information believed to be reliable herein prepared all material. The information contained herein is not guaranteed by Bold to be accurate, and should not be considered to be all-inclusive. The owner, publisher, editor and their associates are not responsible for errors and omissions. They may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. Any opinions expressed are subject to change without notice. Bold encourages readers and investors to supplement the information in these reports with independent research and other professional advice. All information on featured companies is provided by the companies profiled, or is available from public sources and Bold makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled companies or the information contained herein. The companies that are discussed in this opinion have not approved the statements made in this opinion. This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Bold is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter. Please consult a broker before purchasing or selling any securities viewed onhttp://www.boldstocks.com or mentioned herein. This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected”, “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a companies= annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and Bold undertakes no obligation to update such statements. Pentony Enterprises LLC is occassionally compensated for coverage. When this is the case, we indicate clearly with a disclosure of all compensation received in the past and present, plus we also disclose any anticipated compensation in the future. Compensation is typically in cash. Sometimes a third party shareholder pays us in free trading shares. Sometimes a company pays us in restricted shares. Pentony Enterprises is not a registered investment adviser or a broker/dealer. Pentony Enterprises LLC makes no recommendation that the purchase of securities of companies profiled in this web site is suitable or advisable for any person, or that an investment in such securities will be profitable. In general, given the nature of the companies profiled and the lack of an active trading market for their securities, investing in such securities is highly speculative and carries a high degree of risk. MZEI Disclosure: Pentony Enterprises LLC was compensated seventy-two hundred dollars and 450,000 144 restricted common shars by the company for profile coverage for the period ending September 15, 2009. Pentony Enterprises is not a registered investment adviser or a broker/dealer. Pentony Enterprises LLC makes no recommendation that the purchase of securities of companies profiled in this web site is suitable or advisable for any person, or that an investment in such securities will be profitable. In general, given the nature of the companies profiled and the lack of an active trading market for their securities, investing in such securities is highly speculative and carries a high degree of risk.